On January 10, 2023 Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, reported the completion and closure of enrollment for the final cohort of patients involved in the Company’s Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer (Press release, Nascent Biotech, JAN 10, 2023, https://www.nascentbiotech.com/nascent-enrolls-final-patient-cohort-in-phase-i-brain-cancer-trial/ [SID1234626148]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the completion of patient dosing in this fifth and final cohort, the Company’s Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research.

"Closing enrollment for this final cohort of our Phase I trial is a tremendous milestone that marks the start of our preparation for Phase II research," noted Nascent CEO, Sean Carrick. "This is a significant accomplishment in the advancement of our Biologic asset and in our mission to help future patients in their battle against this terrible disease."

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.